# A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

> **NCT01314898** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** 3 mg PF-03882845
- **DRUG:** 10 mg PF-03882845
- **DRUG:** 30 mg PF-03882845
- **DRUG:** 100 mg PF-03882845
- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT01314898
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2011-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01314898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01314898, "A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01314898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*